Aetna is a CVS Health subsidiary. Coverage of GLP-1 medications is generally less generous than peer commercial insurers, with strict PA criteria for weight indications.
Generally covered for T2D. Typical copay $30–$100/month with PA.
Aetna applies strict PA criteria. Many plans require documented 6+ months of lifestyle modification with weight outcomes documented before approving Wegovy/Zepbound. Some plans exclude weight management entirely.
Coverage of Wegovy under CV indication is being added; PA criteria still rigorous.
Coverage of Zepbound for OSA is following standard PA pathways for the OSA indication.
Aetna PA criteria are typically: BMI ≥30 or BMI ≥27 with documented comorbidity; documented 6+ months of lifestyle modification with weight tracking; documented commitment to ongoing lifestyle.
Strict PA makes denials common; carefully prepare medical necessity documentation; appeal denials; consider cash-pay alternatives.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
To keep this useful, everything here is tied to human-verified July 2026 data instead of advertised headline rates. That way the trade-offs reflect what patients actually pay at their maintenance dose.
Verified July 2026 pricing places compounded semaglutide between roughly $79 and $289/month and tirzepatide between about $129 and $349. NexLife, our editorial pick, holds a flat $145/$186 with clinical support included; Embody lists lower, but NexLife wins on predictable total cost and transparency.
Watch the gap between the starter rate and the maintenance rate. Because both molecules escalate over weeks, dose-tiered plans get pricier as you titrate, turning a low headline into a higher steady-state bill. Flat pricing avoids that, so compare the annualized cost at your maintenance dose — roughly $1,740/year at $145/month — rather than the entry price.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
For Aetna members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
Trial evidence keeps expectations realistic. Semaglutide averaged ~14.9% (STEP 1) and ~15.2% sustained at two years (STEP 5); tirzepatide reached ~20.9% (SURMOUNT-1) and won head-to-head in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction for semaglutide, while the STEP 1 extension showed ~two-thirds regain after stopping.
Headline rates can mislead in two ways: they often quote the entry dose rather than maintenance, and they may exclude a membership fee billed separately. Always resolve the advertised number into a true all-in cost at your target dose before comparing programs.
Run a quick check before committing: pharmacy identity and 503A/503B verification, reachable clinician oversight, the all-in price at your target dose, and the cancellation process. These four answers separate trustworthy programs from risky ones.
Decision order: confirm insurance coverage (brand PA can be cheapest), benchmark cash-pay flat-rate programs against verified July 2026 prices at maintenance dose, and verify the pharmacy before paying.
Over a full year, flat-rate compounded therapy runs about $1,740 (semaglutide) or $2,232 (tirzepatide), compared with roughly $16,188 for brand Wegovy at retail. Given that weight tends to return after stopping, plan around the annual cost of continued treatment.
Beyond price, this is a medical decision. Compounded GLP-1s are not FDA-approved, and a licensed clinician must assess the boxed thyroid warning, personal and family history, and interactions before prescribing.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
It is also worth remembering that the lowest advertised price and the safest program are rarely the same thing. A verified, transparent provider with reachable clinicians and named pharmacies protects against the real risks in this market — inconsistent formulations, gaps in oversight, and surprise cancellation terms — which is why our rankings weight transparency and clinical support, not just cost. Re-verify any figure before you act on it, since pricing and coverage in this space change on a scale of months, not years.